NCT00191607CompletedPhase 3
A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 162
- Locations
- 2
- Primary Endpoint
- - Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments
Study Overview
Brief Summary
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as the period from study entry until disease progression
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients must have a documented pathologic diagnosis of epithelial ovarian (FIGO Stage I-IV), Fallopian tube or primary peritoneal carcinoma
- •Patients must have received platinum-based, first-line chemotherapy but no more than one additional prior chemotherapy regimen. Patients must have recovered from the acute side effects of prior chemotherapy prior to enrollment in this trial.
- •Patients must be considered to have platinum resistant disease based on the most recent platinum-based regimen given, i.e., have had a treatment-free interval in response to platinum of less than six months, or have progressed during platinum-based therapy
- •Presence of measurable disease or CA-125 > or = to 100 on two separate occasions at least one week apart is required for this study
- •Patient must have a Zubrod Performance Status of 0, 1 or 2
- •Patients with a current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) are not eligible. Patients with a prior diagnosis of a low malignant potential tumor that was surgically resected and who have subsequently developed invasive adenocarcinoma are eligible.
- •Patients who are currently undergoing abdominal or pelvic radiation therapy or patients who have received prior abdominal or pelvic radiation therapy are excluded.
- •Patients with unstable angina or who have had a heart attack within the past six months are not eligible to participate.
- •Patients who have received prior Gemzar or Doxil therapy are ineligible.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments
Secondary Outcomes
- Secondary objectives:
- Response rate
- Duration of response
- Time to treatment failure
- Survival
- Quality of life
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 2
Doxil and Gemcitabine in Recurrent Ovarian CancerOvarian CarcinomaNCT00312650Women and Infants Hospital of Rhode Island24
Completed
Phase 3
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic AgentsBreast NeoplasmsNCT00191438Eli Lilly and Company300
Completed
Phase 3
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial CancerRecurrent Uterine Corpus CarcinomaStage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7Stage IVB Uterine Corpus Cancer AJCC v7NCT00063999GOG Foundation1,381
Active, not recruiting
Phase 3
Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.Metastatic Castration-resistent Prostate CancerNCT04139772National Cancer Institute, Naples18
Unknown
Phase 2
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II StudyPeripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell LymphomaHepatosplenic Gamma/ Delta T-cell LymphomaEnteropathy-Associated T-Cell LymphomaNCT01719835Royal Marsden NHS Foundation Trust87